SEARCH

SEARCH BY CITATION

References

  • 1
    World Health Organization 2005. Preventing chronic diseases: a vital investment. WHO global report. http://www.who.int/chp/chronic_disease_report/en/ [Last Accessed 21st April 2009].
  • 2
    Asadi-Laria M, Sayyarib AA, Akbaric ME, Gray D. Public health improvement in Iran - lessons from the last 20 years. Public Health 2004; 118: 395402.
  • 3
    Rastegarpanah M, Malekzadeh F, Thomas GN, Mohagheghi A, Cheng KK, Marshall T. A new horizon in primary prevention of cardiovascular disease, can we prevent heart attack by “heart polypill”? Arch Iran Med 2008; 11: 30613.
  • 4
    Larijani B, Fakhrzadeh H, Mohaghegh M, Pourebrahim R, Akhlaghi MR. Burden of coronary heart disease on the Iranian oil industry (1999-2000). East Mediterr Health J 2003: 9:90410.
  • 5
    Law MR, Wald NJ, Wu T, Hackshaw A, Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. Br Med J 1994; 308: 3636.
  • 6
    MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 76574.
  • 7
    Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 190313.
  • 8
    Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. Br Med J 2002; 324: 15706.
  • 9
    Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br Med J 2003; 326: 14236.
  • 10
    Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 82739.
  • 11
    Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U. S. Preventive Services Task Force. Ann Inter Med 2002; 136: 16172.
  • 12
    Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. Br Med J 2003; 326: 1419.
  • 13
    Guglietta A, Guerrero M. Issues to consider in the pharmaceutical development of a cardiovascular polypill. Nat Clin Pract Cardiovasc Med 2009; 9: 1129.
  • 14
    Frishman WH, Zuckerman AL. Amlodipine/atorvastatin: the first cross risk factor for polypill for the prevention and treatment of cardiovascular disease. Expert Rev Cardiovasc Ther 2004; 3: 67581.
  • 15
    Clinical Trials Research Unit. The University of Auckland (online 2008) PILL Pilot: Programme to Improve Life and Longevity [ http://www.ctru.auckland.ac.nz/content/view/37/35/]. (Last accessed 5th February 2009).
  • 16
    Xavier D, Pais P, Sigamani A et al. Investigators The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study. Nat Clin Pract Cardiovasc Med 2009; 9: 967.
  • 17
    Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet 2006; 368: 67986.
  • 18
    Combination Pharmacotherapy and Public Health Research Working Group. Combination pharmacotherapy for cardiovascular disease. Ann Inter Med 2005;143:5939.
  • 19
    Reddy KS. The preventive polypill – much promise, insufficient evidence. N Engl J Med 2007; 356: 3.
  • 20
    Health System Profile Islamic Republic of Iran. Regional Health Systems Observatory, World Health Organization, 2009. [Last accessed 21st April 2009] http://gis.emro.who.int/HealthSystemObservatory/PDF/Iran/Full%20Profile.pdf.
  • 21
    Kamangar F, Malekzadeh R, Dawsey SM, Saidi F. Esophageal cancer in Northeastern Iran: a review. Arch Iran Med. 2007; 10:7082. review.
  • 22
    Pourshams A, Saadatian-Elahi M, Nouraie M et al. Golestan cohort study of oesophageal cancer: feasibility and first results. Br J Cancer 2005; 92: 17681.
  • 23
    Bahrami H, Sadatsafavi M, Pourshams A et al. Obesity and hypertension in an Iranian cohort study; Iranian women experience higher rates of obesity and hypertension than American women. BMC Public Health 2006; 6: 158.
  • 24
    Effect of a Polypill on middle-aged and elderly Iranians http://www.controlled-trials.com/ISRCTN43076122/ [Last accessed 15th January 2008].
  • 25
    Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Br Med J 2003; 326: 142732.
  • 26
    The Indian Polycap Study (TIPS) Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009; 373: 13411351. Published Online March 30, 2009. DOI:10.1016/S0140-6736(09)60611-5.
  • 27
    Final report on the aspirin component of the ongoing Physicians’ Health Study. Steering Committee of the Physicians’ Health Study Research Group. N Engl J Med 1989; 321:12935.
  • 28
    Peto R, Gray R, Collins R et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988; 296: 3136.
  • 29
    The Medical Research Council’s General Practice Research Framework. Thrombosis prevention trial: randomised trial of low intensity oral anticoagulation with warfarin and low dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. Lancet 1998; 351: 23341.
  • 30
    Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 175562.
  • 31
    Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001; 357: 8995.
  • 32
    Ridker PM, Cook NR, Lee IM et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293304.
  • 33
    Ogawa H, Nakayama M, Morimoto T et al. Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) Trial Investigators. low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. J Am Med Assoc 2008; 300: 213441.
  • 34
    Belch J, MacCuish A, Campbell I et al. Prevention of Progression of Arterial Disease and Diabetes Study Group, Diabetes Registry Group, and Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. Br Med J 2008; 337: a1840.
  • 35
    Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003; 21: 70716.
  • 36
    Ridker PM, Danielson E, Fonseca FAH, for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195207.
  • 37
    Cholesterol Treatment Trialists’ (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 126778.
  • 38
    Antithrombotic Trialists’ (ATT) Collaboration Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 184960.